EN | UA
EN | UA

Help Support

Back

mRNA COVID-19 vaccine found safe in cancer patients receiving treatment for solid tumors

mRNA COVID-19 vaccine found safe in cancer patients receiving treatment for solid tumors mRNA COVID-19 vaccine found safe in cancer patients receiving treatment for solid tumors
mRNA COVID-19 vaccine found safe in cancer patients receiving treatment for solid tumors mRNA COVID-19 vaccine found safe in cancer patients receiving treatment for solid tumors

What's new?

mRNA COVID-19 vaccine can be safely used in cancer people receiving various systemic treatments for solid tumors.

A prospective, non-inferiority, multicenter study (VOICE trial) carried out by S. Oosting et al. found that messenger RNA (mRNA)-1273 vaccine is safe against coronavirus in cancer patients receiving chemotherapy, immunotherapy, or chemo-immunotherapy for solid tumors and resulted in a high seroconversion rate that was comparable to the control group (people without cancer).

Cancer patients have an elevated risk of complications from SARS-CoV-2 infections. Therefore, researchers aimed to explore the safety and immunogenicity of the messenger RNA-1273 COVID-19 vaccine in cancer people who were being treated for solid tumors.

Participants were divided into four cohorts: (i) Cohort A: People without cancer, (ii) Cohort B: People with solid tumors who were given immunotherapy, (iii) Cohort C: Patients treated with chemotherapy, and (iv) Patients treated with chemo-immunotherapy. The recruited people were given 2 doses of the vaccine twenty-eight days apart.

The major outcome was coronavirus Spike S1-specific IgG serum antibody response, defined as >10 binding antibody units (BAU)/ml 28 days following the 2nd  vaccination. The SARS-CoV-2 neutralizing capacity of these antibodies, adverse events, and coronavirus Spike-specific interferon-gamma T cell response were also examined.

Notably 743 out of 791 people were evaluable for the major outcome parameter in cohort A (n=240), B (n=131), C (n=229) and D (n=143). Table 1 illustrates the percentage of people in which SARS-CoV-2-binding antibody response was noted. For distinguishing between adequate and suboptimal responders, a cut-off level at 300 BAU/ml was defined on the basis of neutralizing capacity.

In cohorts A, B, C, and D, the antibody response was noted to be adequate in 66%, 37.1%, 32.5%, and 33.3% of people respectively after the 1st vaccination. After the second vaccination, the  antibody response is depicted in Table 1:


In 46.7% of suboptimal and non-responders, the spike-specific T cell responses were noted. There were no novel safety signals.

For each of the cohort with solid tumors, the percentage of people having a SARS-CoV-2-binding antibody response after 2 vaccinations showed non-inferiority in comparison with people without cancer. But, a considerable minority lacks a satisfactory response. The majority of the people exhibited a rise in antibody concentration after 2nd vaccination. Thus, an additional booster might turn inadequate responders into adequate responders.

Source:

Practice Update

Article:

ESMO 2021: Messenger RNA COVID-19 Vaccine Safe for Patients on Treatment for Solid Tumors

Authors:

S. Oosting et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: